Homozygous Familial Hypercholesterolemia
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
CRITERIA LIST/ QUALIFICATIONS:
- Initiating treatment with lomitapide at the time of registry enrolment, or initiated treatment with lomitapide within 15 months prior to enrolment into the registry and after lomitapide commercial availability in the country.
- Patients who have the ability to understand the requirements of the study and provide written informed consent to comply with the study data collection procedures.
Thomas Knickelbine, MD
Aegerion Pharmaceuticals, Inc.